Introduction
T h e biological activities of oestrogens are mediated by the oestrogen receptor (ER), which binds the steroidal ligand and transduces its signal to the nuclear genetic apparatus. This protein is a member of the steroid/thyroid hormone receptor gene superfamily of ligand-activated transcription factors whose members positively or negatively regulate transcription of target genes by binding to &-acting DNA sequences, called hormone-responsive elements, in the 5'-flanking regions of responsive genes [ 13. Our current understanding of the process of ligand-regulated, steroid receptor-mediated biological activity is derived from studies of ER and other steroid receptor superfamily members. Briefly, non-protein-bound steroid diffuses across the plasma membrane of target cells whereupon receptor proteins are able to bind their cognate ligand with high affinity. These receptors subsequently undergo a conformational change and dissociate from an inhibitory heterAbbreviations used: AP, activator protein; EGF, epidermal growth factor; ER, oestrogen receptor; IGF-1, insulin-like growth factor-1; PMA, phorbol 12-myristate 13-acetate. *To whom correspondence should be addressed. oligomeric complex of receptor and heat shock and other proteins [Z-51, dimerize and bind specifically to their response elements [6-81. These DNA sequences, such as the consensus oestrogen-response element, GGTCAnnnT-GACC, are typically found within the regulatory regions of steroid-sensitive genes and function as enhancers since they confer steroid-responsiveness regardless of orientation and position with respect to their target gene promoters [9-111. Subsequent receptor modifications such as phosphorylation by DNA-dependent and other kinases occur, and interactions with the general transcriptional apparatus and/or specific cofactors enable receptors to alter gene transcription [12] [13] [14] .
Phosphorylation and ER transcriptional activity
Reversible, post-translational, phosphorylationl dephosphorylation reactions are extensively utilized as regulators of intracellular functions as diverse as glucose metabolism, gene transcription and cell-cycle control, and it was first suggested more than 30 years ago [15] that phosphorylation could influence steroid receptor activity. Indeed, all of the steroid receptors studied to date, including the ER, are phospho-proteins, and increases in overall receptor phosphorylation as well as increased phosphorylation of specific amino acid residues have been demonstrated following exposure of cells to the receptor's cognate ligand (reviewed in [16] ). For example, oestrogen has been demonstrated to increase phosphorylation of endogenous ER in MCF-7, rat and mouse uterine cells [17-191, as well as ER transiently expressed in Sf9 and COS cells [20, 21] , while mutant mouse ERs defective in either oestrogen or DNA binding are phosphorylated at reduced levels relative to wild-type receptors [22] . Ser-167, identified by radiolabelling and amino acid sequence analysis, has been reported to be the major oestrogen-induced phosphorylation site of human ER [ZO] . Other studies have revealed Ser-104 and/or -106 and Ser-118 as the major oestrogen-inducible phosphorylation sites, and mutation of these amino acids from serine to alanine residues reduces the overall oestrogen-dependent phosphorylation of ER as well as its ability to mediate the transcription of various reporter constructs, suggesting that enhanced site-specific receptor phosphorylation may directly influence gene expression [21, 23] . The reason for these contrasting data is not known, but a possible explanation may be cell-specific utilization of multiple potential phosphorylation sites. Indeed, the observation that the anti-oestrogens 4-hydroxytamoxifen and ICI 164,384 also increase overall ER phosphorylation [ 17, 21, 23] indicates that the relationship between phosphorylation and transcriptional activation is complex.
Current models of ligand-dependent steroid receptor activation include multiple phosphorylation steps [ 13, 14, 16] , and all instances of ligandindependent activation of steroid receptor superfamily members also require the use of compounds, either synthetic or naturally occurring, capable of altering cellular phosphorylation pathways. The mechanism by which steroid receptors are activated in the apparent absence of ligand are not currently understood, but it is presumed that their phosphorylation andlor phosphorylation of other rate-limiting co-factors with which receptors must interact to facilitate transcription are intimately involved in enhancing target gene expression. It is important to note in the discussion below that our definition of ligand-independent activation relates to receptor-dependent target gene transcription in the absence of ligand. It should be appreciated, however, that certain cells may produce a sub-936 stance(s) that receptors bind with low affinity or that low-abundance oestrogens may be present in culture media, and thus we are unable to discount the presence of very weak agonists in experimental systems.
Ligand-independent activation of oestrogen receptor
Several laboratories have examined the ability of ER to be activated in a ligand-independent fashion. Cho and Katzenellenbogen [24] used activators of protein kinase A (cholera toxin) in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine as well as the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) to treat MCF-7 and CHO cells, and in neither case was an increase in ERdependent reporter gene expression observed in the absence of oestradiol. The human ER, however, has been ligand-independently activated by okadaic acid in CVI cells [25] , and the transcription-enhancing activity of rat uterine ER is ligand-independently stimulated by cholera toxin, 3-isobutyl-1-methylxanthine and 8-bromo-cyclic AMP [17] . The inability of the protein kinase activators mentioned above to modulate ligandindependent ER activity in MCF-7 and CHO cells may reflect promoter-or cell-type-specific differences. Indeed, the ability of PMA to synergize with oestradiol in the activation of ERdependent transcription is known to vary with these two parameters [24] .
In addition to pharmacological modulators of cellular phosphorylation levels, the catecholaminergic neurotransmitter, dopamine, dosedependently stimulates ER-dependent gene expression in the absence of oestradiol via a signal transduction pathway initiated from dopamine receptors of the D1 subtype within the plasma membrane of CV, and HeLa cells [25, 26] . Human ER also has been activated by synthetic, full D1-receptor agonists such as SKF 82958 in the neuroblastoma cell line, SK-N-SH (E. Gangolli, 0. M. Conneely and B. W. O'Malley, unpublished work) and HeLa cells. This confirms that ER ligand-independent activation is not restricted to a single cell type and suggests that a similar activation of ER may occur in other cell types that express functional dopamine receptors of this general subtype. Nevertheless, it is probable that dopamine-stimulated ER transcriptional activity will vary with cell type and the promoter context of the target gene.
It has been suggested that ligand-indepen- Volume 23 dent activation of steroid receptors may represent activation of non-receptor transcription factors that synergize with members of the steroid receptor superfamily to increase target gene expression in the absence of steroid ligand [27] . In particular, a potential activator protein (AP)-l site resides within the plasmid backbone of many commonly used synthetic reporter genes, including the one, ERE-e 1 b-CAT, utilized in our studies. We have therefore determined whether this site was responsible for dopaminergic activation of ER-dependent transcription in HeLa cells. In parallel experiments, the intact ERE-elb-CAT reporter gene or a similar target construct, in which the proposed AP-1 site has been removed by deletion of the EcoOlO91 to NdeI region of the plasmid, was transiently transfected along with a human ER expression vector. Relative to 1 nM oestradiol, the dopamine-receptor agonist SKF 82958 was approximately 60% as effective at stimulating CAT gene expression when the potential AP-1 site was deleted compared with when the intact reporter gene construct was utilized (Figure 1) . Thus although the region of reporter plasmid encompassing the AP-1 site does contribute towards the overall transcription-enhancing activity of ER, it is neither necessary nor sufficient for ligand-independent activation of ER in this test system. Peptide growth factors are a third class of agent able to ligand-independently activate ERdependent transcription. Indeed, it has been known for several years that epidermal growth factor (EGF) and insulin-like growth factor-1 (IGF-1), in addition to the phorbol ester, PMA, and elevated intracellular CAMP levels, increase progesterone receptor synthesis in foetal uterine and MCF-7 breast cancer cells, and the ability of anti-oestrogens to block these effects supported the suggestion that ER may be activated in a ligand-independent fashion [ 17,28-3 13. Furthermore, EGF mimics the oestrogen-induced production of the iron-binding glycoprotein lactoferrin, as well as promoting growth in mouse uterus [32] . Epidermal growth factor also induces biochemical changes in mouse uterine ER in oioo, such as increased DNA binding and production of heterogeneous forms of nuclear receptor, indicating that this peptide modulator of cellular phosphorylation pathways is able to influence ER in living animals [33] . Direct evidence for peptide-growth-factor activation of ligand-independent ER-dependent gene expression has been obtained in multiple cell types, suggesting wide-spread utilization of this mode of receptor activation. Transforming growth factor-cc or EGF stimulation of HeLa, Ishikawa (endometrial) and BG-1 (ovarian) cells transiently transfected with ER-responsive target genes results in dose-dependent activation of ER in an oestrogen-independent manner, and this transcriptional activation was blocked by the pure anti-oestrogen, ICI 164,384 [34, 35] . Furthermore, ER-mediated activation of a synthetic target gene has been observed following IGF-1 treatment of primary rat uterine cell cultures in the absence of oestrogen, and this effect is also inhibited by co-administration of ICI 164,384 [ 171. In addition, IGF-1 treatment results in enhanced overall phosphorylation of endogenous ER isolated from these cells, suggesting phosphorylation may play a role, either directly or indirectly, in mediating the ligand-independent transcriptional activation of ER. T o date, no ligand-independent phosphorylation sites have been mapped, and the interesting possibility of a mutually exclusive ligand-dependent and/or ligand-independent phosphorylation site(s) still remains.
Significance of ER ligand-independent activation
In females, ER is concentrated in reproductive organs and the growth and differentiation of these tissues is influenced by oestradiol. This steroid increases the mRNA and/or protein levels 
Model for the ligand-dependent and ligand-independent activation of ER in female reproductive tissues
In the classical model of steroid hormone action, inactive ER binds its cognate ligand, oestradiol (EJ, is then activated (ER*), binds to an oestrogen response element (ERE) and through interaction with the general transcriptional machinery, expression of target genes such as EGF and its receptor is activated. In the Iigand-independent model, unliganded ER may be activated by a growth-factor-initiated signalling pathway and thereby increase ER-dependent gene expression; receptor may be nuclear (n) and already bound to an ERE (right pathway)
or not yet associated with DNA. It is also possible that oestradiol and growth factor may simultaneously actvate the ER to increase the overall level of target gene activation (left pathway), and in either case increased gene expression may also arise through modification of transcription co-factors able to interact with ER. These pathways may also allow oestradiol-stimulated gene transcription to be amplified since oestradiol increases certain growth factor and growth factor receptor levels and these gene products may in turn further activate ER-dependent gene transcription. from these cell-surface receptors to steroid receptor superfamily members are presently unknown but are likely to be complex and involve multiple downstream kinases and/or phosphatases. We believe it probable that ligand-dependent and -independent pathways may be utilized under many physiological situations, and the relative contributions of these pathways to the activation of steroid receptor superfamily members should therefore be considered when evaluating steroid receptor function in vivo. In fact it is quite possible under certain conditions that the dominant activation mechanism for selected receptors may be initiated by a membrane-receptor-transduced signal. In addition to normal physiological situations, the implication of ligand-dependent and -independent activation of the ER for the initiation, progression and ultimately the management of cancers such as breast, ovarian and endometrial could be important; of special interest would be oestrogen-independent or tamoxifen-resistant tumours. Future consideration to both ER-activation mechanisms may be prudent in planning the treatment of these diseases.
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